Steven Cohen, MD
Medical Oncology · Abington, PANPI 1538136833
Payments from drug & device makers
Across 37 payments — averaging $1121.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$8K
- Halozyme Inc$5K
- Merck$5K
- E.r. Squibb & Sons, L.L.C.$4K
- Deciphera Pharmaceuticals Inc.$4K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- plus $13K from 15 others
What the payments were for
- Consulting fees$28,25578%
- Speaking & faculty fees$6,23017%
- Travel & lodging$2241%
- Food & beverage$1,2814%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 4 | $7,813 |
| Halozyme Inc | 1 | $5,450 |
| Merck | 4 | $5,005 |
| E.r. Squibb & Sons, L.L.C. | 4 | $3,963 |
| Deciphera Pharmaceuticals Inc. | 3 | $3,712 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,760 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $2,720 |
| AstraZeneca | 2 | $2,043 |
| Taiho Oncology, Inc. | 1 | $1,950 |
| Ipsen Biopharmaceuticals, Inc | 1 | $1,550 |
| Seagen Inc. | 1 | $1,375 |
| Incyte Corporation | 2 | $1,166 |
| Bayer | 1 | $1,028 |
| Tempus AI, Inc | 4 | $381 |
| Boston Scientific | 1 | $144 |
| Rigel Pharmaceuticals, Inc. | 1 | $125 |
| Astellas Pharma US Inc | 1 | $122 |
| Intuitive Surgical | 1 | $69 |
| Eisai Inc. | 1 | $66 |
| Caris MPI, Inc. | 1 | $25 |
| Davol Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,483 in reported general payments places this provider in the 50th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 57 | $590 |
| Ondansetron Hcl | 48 | $315 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $122 |
| Oxycodone Hcl | 12 | $111 |
| Tramadol Hcl | 14 | $67 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Abington
- Sukhmani PaddaPhiladelphia$25.6M
- Peter O DwyerPhiladelphia$18M
- Margaret von MehrenPhiladelphia$17.4M
- Kim Reiss BinderPhiladelphia$16.9M
- Carl JunePhiladelphia$13M
- Takami SatoPhiladelphia$11.5M
- Vivek NarayanPhiladelphia$10.6M
- Ubaldo Martinez-OutschoornPhiladelphia$10.5M
- Neil PalmisianoPhiladelphia$10.1M
- Anthony OlszanskiPhiladelphia$9.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.